Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence-Reference-Cited by-同舟云学术

Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence

Published:2012-01 Issue:1 Volume:39 Page:11-15
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Nicolau David P.,Carmeli Yehuda,Crank Christopher W.,Goff Debra A.,Graber Christopher J.,Lima Ana Lucia L.,Goldstein Ellie J.C.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference19 articles.

1. Collateral damage and what the future might hold. The need to balance prudent antibiotic utilization and stewardship with effective patient management;Weber;Int J Infect Dis,2005

2. International study of the prevalence and outcomes of infection in intensive care units;Vincent;JAMA,2009

3. Antimicrobial stewardship lessons: do Pseudomonas-sparing agents, such as ertapenem, effectively improve bacterial resistance?;Pires dos Santos;Antimicrob Agents Chemother,2010

4. ‘Collateral damage’ from cephalosporin or quinolone antibiotic therapy;Paterson;Clin Infect Dis,2004

5. Extended-spectrum β-lactamases: a clinical update;Paterson;Clin Microbiol Rev,2005

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors and clinical impact of multidrug resistance in healthcare-associated bacteraemic urinary tract infections: a post-hoc analysis of a multicentre prospective cohort in Spain;Journal of Hospital Infection;2024-09

2. Revealing an Abundance of Microbial Fecal Contamination and Multidrug Resistant Bacteria in the Mississippi Gulf Coast;Water;2023-06-24

3. Best practices: Appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa;Southern African Journal of Infectious Diseases;2022-10-20

4. Thirty-Day Mortality Rates in Patients with Extended-Spectrum β-Lactamase-Producing Enterobacterales Bacteremia Receiving Ertapenem versus Other Carbapenems;Antimicrobial Agents and Chemotherapy;2022-07-19

5. Aspectos generales sobre la resistencia bacteriana de gérmenes productores de β-lactamasas tipo AMPC: una revisión narrativa;Revista de la Facultad de Ciencias de la Salud Universidad del Cauca;2022-07-01